Latest Trovagene Inc (TROV) Headlines
Trovagene Schedules Release of Fourth Quarter and Year End 2013 Financial Results and Investor Conference Call
PR Newswire - Mon Mar 03, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter and year ended December 31, 2013 on Monday, March 17, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
3 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 28, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Dr. Rodney S. Markin Joins Trovagene's Board of Directors
PR Newswire - Wed Feb 19, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Dr. Rodney S. Markin has joined the Company's Board of Directors. Dr. Markin is a hepatic pathologist by training, and is a leading authority in the field of laboratory automation.
Trovagene to Present at Two Upcoming Investor Conferences
PR Newswire - Thu Feb 06, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the following 2014 healthcare and investor conferences next week in New York: BIO CEO & Investor Conference and Leerink Global Healthcare Conference.
Nasdaq stocks posting largest percentage decreases
AP - Mon Feb 03, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Trovagene and US Oncology Research Collaborate on a Prospective Study for Urine-based KRAS Testing in Patients with Metastatic Pancreatic Cancer
PR Newswire - Mon Jan 06, 4:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, and US Oncology Research, one of the largest community-based research programs in the United States, announced today that they have entered into a Clinical Study Agreement to examine the utility of quantitative urine-based KRAS mutation detection and monitoring in pancreatic cancer patients. US Oncology Research draws from a network of experienced investigators and clinical staff who specialize in Phase I through Phase IV oncology clinical trials. In addition to the 11 US Oncology Research affiliated community cancer care sites participating in this study, academic research institutions that specialize in oncology have also elected to participate.
Trovagene to Present at 25th Annual Piper Jaffray Conference
PR Newswire - Mon Dec 02, 4:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the Piper Jaffray 25th Annual Healthcare Conference.
Empire Asset Management terminates coverage on TrovaGene (NASDAQ:TROV).
PR Newswire - Fri Nov 22, 10:07AM CST
Effective today Empire Asset Management Company, a FINRA member (143007) terminated coverage of TrovaGene (NASDAQ:TROV). We are discontinuing coverage of TrovaGene Inc because the analyst covering the company is no longer associated with the firm. Shares of TrovaGene have been rated a buy since May 6, 2013. Investors should no longer rely on Empire Asset Management research for an investment recommendation on TrovaGene.
Global Cancer Diagnostic Testing Market Report 2013
M2 - Fri Nov 15, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/fp8dbc/cancer_diagnostic) has announced the addition of the "Global Cancer Diagnostic Testing Market Report 2013" report to their offering. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Abbott Diagnostics - Bard Diagnostics, Inc. - Byk Gulden - Cepheid - DRG International, Inc. - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Geron Corporation - Hologic, Inc. (formerly Cytyc Corporation) - Immunicon Corporation (now Veridex, LLC) - Immunomedics, Inc. - LabCorp - Myriad Genetics, Inc. - Nexell Therapeutics, Inc. - Oncotech, Inc. - Polymedco, Inc. - Princeton BioMeditech Corporation - Qiagen - Roche (F. Hoffman-La Roche, Ltd.) - Sanko Junyaku Co., Ltd. - Siemens Heathcare Diagnostics - Tosoh Corporation (Bioscience division) - Ventana Medical Systems, Inc. - Veridex, LLC - Vermillion, Inc. - Worldwide Medical Corporation - Xenomics, Inc. (TrovaGene, Inc.) For more information visit http://www.researchandmarkets.com/research/fp...diagnostic
Trovagene, Inc. Reports Third Quarter 2013 Financial Results
PR Newswire - Thu Nov 14, 3:00PM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported financial results for the three months and the nine months ended September 30, 2013.
Trovagene Schedules Release of Third Quarter 2013 Financial Results and Hosts Investor Conference Call
PR Newswire - Fri Nov 08, 4:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter ended September 30, 2013 on Thursday, November 14, 2013 at 4:00 p.m. Eastern Standard Time (1:00 p.m. Pacific Standard Time).
Trovagene Inc names Dr. Paul R. Billings to board
M2 - Thu Oct 31, 10:44AM CDT
Molecular diagnostics company Trovagene Inc (NASDAQ:TROV) reported on Wednesday the addition of Dr Paul R. Billings to its board of directors.
Dr. Paul Billings Joins Trovagene's Board of Directors
PR Newswire - Wed Oct 30, 3:00PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Dr. Paul R. Billings has been appointed to the Company's Board of Directors. A board certified internist and clinical geneticist, Dr. Billings currently serves as Chief Medical Officer at Life Technologies Corporation and is a member of Trovagene's Scientific Advisory Board. He is highly regarded as an experienced leader in the field of molecular diagnostics.
First Prospective Cancer Monitoring Data Released - Indicating that Oncogene Mutation Signal in Urine Correlates with Response to Therapy
PR Newswire - Mon Oct 21, 11:30AM CDT
Trovagene Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced that study findings presented today demonstrate that the company's novel, non-invasive oncogene mutation detection technology can be a clinically useful cancer-monitoring tool. In collaboration with scientists at Trovagene, Dr. Filip Janku of The University of Texas MD Anderson Cancer Center presented findings from an ongoing clinical study of Trovagene's technology at the AACR-NCI-EORTC[1] International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA.
Trovagene announces pharmaceutical collaboration for oncogene mutation detection study
PR Newswire - Wed Oct 16, 4:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it will collaborate with a pharmaceutical company to evaluate Trovagene's proprietary, urine-based, cell-free DNA technology for the detection of certain epidermal growth factor receptor (EGFR) mutations associated with lung cancer.
Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
PR Newswire - Mon Oct 14, 4:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that two abstracts (#B175 and #B177) highlighting results from studies of the company's novel, non-invasive cancer mutation monitoring platform will be presented on October 21, 2013 at the AACR-NCI-EORTC[1] International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA.
Trovagene Schedules Release of Fourth Quarter and Year End 2013 Financial Results and Investor Conference Call
PR Newswire - Mon Mar 03, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter and year ended December 31, 2013 on Monday, March 17, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
3 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 28, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Dr. Rodney S. Markin Joins Trovagene's Board of Directors
PR Newswire - Wed Feb 19, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Dr. Rodney S. Markin has joined the Company's Board of Directors. Dr. Markin is a hepatic pathologist by training, and is a leading authority in the field of laboratory automation.
Trovagene to Present at Two Upcoming Investor Conferences
PR Newswire - Thu Feb 06, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the following 2014 healthcare and investor conferences next week in New York: BIO CEO & Investor Conference and Leerink Global Healthcare Conference.
Nasdaq stocks posting largest percentage decreases
AP - Mon Feb 03, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Trovagene and US Oncology Research Collaborate on a Prospective Study for Urine-based KRAS Testing in Patients with Metastatic Pancreatic Cancer
PR Newswire - Mon Jan 06, 4:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, and US Oncology Research, one of the largest community-based research programs in the United States, announced today that they have entered into a Clinical Study Agreement to examine the utility of quantitative urine-based KRAS mutation detection and monitoring in pancreatic cancer patients. US Oncology Research draws from a network of experienced investigators and clinical staff who specialize in Phase I through Phase IV oncology clinical trials. In addition to the 11 US Oncology Research affiliated community cancer care sites participating in this study, academic research institutions that specialize in oncology have also elected to participate.
Trovagene to Present at 25th Annual Piper Jaffray Conference
PR Newswire - Mon Dec 02, 4:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the Piper Jaffray 25th Annual Healthcare Conference.
Empire Asset Management terminates coverage on TrovaGene (NASDAQ:TROV).
PR Newswire - Fri Nov 22, 10:07AM CST
Effective today Empire Asset Management Company, a FINRA member (143007) terminated coverage of TrovaGene (NASDAQ:TROV). We are discontinuing coverage of TrovaGene Inc because the analyst covering the company is no longer associated with the firm. Shares of TrovaGene have been rated a buy since May 6, 2013. Investors should no longer rely on Empire Asset Management research for an investment recommendation on TrovaGene.
Global Cancer Diagnostic Testing Market Report 2013
M2 - Fri Nov 15, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/fp8dbc/cancer_diagnostic) has announced the addition of the "Global Cancer Diagnostic Testing Market Report 2013" report to their offering. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Abbott Diagnostics - Bard Diagnostics, Inc. - Byk Gulden - Cepheid - DRG International, Inc. - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Geron Corporation - Hologic, Inc. (formerly Cytyc Corporation) - Immunicon Corporation (now Veridex, LLC) - Immunomedics, Inc. - LabCorp - Myriad Genetics, Inc. - Nexell Therapeutics, Inc. - Oncotech, Inc. - Polymedco, Inc. - Princeton BioMeditech Corporation - Qiagen - Roche (F. Hoffman-La Roche, Ltd.) - Sanko Junyaku Co., Ltd. - Siemens Heathcare Diagnostics - Tosoh Corporation (Bioscience division) - Ventana Medical Systems, Inc. - Veridex, LLC - Vermillion, Inc. - Worldwide Medical Corporation - Xenomics, Inc. (TrovaGene, Inc.) For more information visit http://www.researchandmarkets.com/research/fp...diagnostic
Trovagene, Inc. Reports Third Quarter 2013 Financial Results
PR Newswire - Thu Nov 14, 3:00PM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported financial results for the three months and the nine months ended September 30, 2013.
Trovagene Schedules Release of Third Quarter 2013 Financial Results and Hosts Investor Conference Call
PR Newswire - Fri Nov 08, 4:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter ended September 30, 2013 on Thursday, November 14, 2013 at 4:00 p.m. Eastern Standard Time (1:00 p.m. Pacific Standard Time).
Trovagene Inc names Dr. Paul R. Billings to board
M2 - Thu Oct 31, 10:44AM CDT
Molecular diagnostics company Trovagene Inc (NASDAQ:TROV) reported on Wednesday the addition of Dr Paul R. Billings to its board of directors.
Dr. Paul Billings Joins Trovagene's Board of Directors
PR Newswire - Wed Oct 30, 3:00PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Dr. Paul R. Billings has been appointed to the Company's Board of Directors. A board certified internist and clinical geneticist, Dr. Billings currently serves as Chief Medical Officer at Life Technologies Corporation and is a member of Trovagene's Scientific Advisory Board. He is highly regarded as an experienced leader in the field of molecular diagnostics.
First Prospective Cancer Monitoring Data Released - Indicating that Oncogene Mutation Signal in Urine Correlates with Response to Therapy
PR Newswire - Mon Oct 21, 11:30AM CDT
Trovagene Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced that study findings presented today demonstrate that the company's novel, non-invasive oncogene mutation detection technology can be a clinically useful cancer-monitoring tool. In collaboration with scientists at Trovagene, Dr. Filip Janku of The University of Texas MD Anderson Cancer Center presented findings from an ongoing clinical study of Trovagene's technology at the AACR-NCI-EORTC[1] International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA.
Trovagene announces pharmaceutical collaboration for oncogene mutation detection study
PR Newswire - Wed Oct 16, 4:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it will collaborate with a pharmaceutical company to evaluate Trovagene's proprietary, urine-based, cell-free DNA technology for the detection of certain epidermal growth factor receptor (EGFR) mutations associated with lung cancer.
Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
PR Newswire - Mon Oct 14, 4:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that two abstracts (#B175 and #B177) highlighting results from studies of the company's novel, non-invasive cancer mutation monitoring platform will be presented on October 21, 2013 at the AACR-NCI-EORTC[1] International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA.
